AI Clinical Decision Support Software: The New Regulatory Reality for Digital Health and Life Sciences, Pt 1

By Darya Lucas

Clinical decision support (CDS) software is evolving rapidly. Artificial intelligence and machine learning have expanded these tools beyond traditional rules-based alerts, enabling software to analyze complex clinical data, identify patterns, prioritize risk, and generate recommendations that may influence clinical decision-making, diagnosis, and treatment.

For digital health, medical device, and life sciences companies, these advances create significant opportunities, but they also raise fundamental regulatory questions. One of the most important is whether a software product remains a clinical decision support tool or falls within the scope of the FDA’s medical device regulatory framework.

That determination can affect product design, clinical evidence strategies, quality system requirements, commercialization plans, and lifecycle management. Companies that address these issues early are often better positioned to preserve flexibility and avoid costly changes later.

The Line Between CDS and SaMD Is Becoming More Complex

Not every CDS product is regulated as a medical device. Under the Federal Food, Drug, and Cosmetic Act, a product’s regulatory status depends largely on its intended use and whether it meets the statutory definition of a medical device under 21 U.S.C. § 321(h). Certain software functions may be excluded from the device definition when applicable statutory criteria are satisfied.

The FDA’s Clinical Decision Support Software Guidance provides insight into how the Agency evaluates whether software functions are intended to support clinical judgment rather than replace or direct it. In practice, however, determining the appropriate regulatory pathway requires more than simply describing a product as “decision support.” Functionality, intended use, clinical workflow, user interaction, and marketing claims all influence the FDA’s assessment.

A tool that organizes and displays clinical information may present different considerations from software that interprets patient-specific data, predicts risk, recommends a diagnosis, or suggests a treatment option. Similarly, software that allows clinicians to independently evaluate the basis for a recommendation may be viewed differently from software that produces outputs through an AI model that users cannot meaningfully assess.

These distinctions are particularly important as AI capabilities expand. Products often evolve to incorporate additional data sources, predictive functionality, and new use cases. A solution initially positioned as a workflow or analytics tool may have different regulatory implications as functionality expands. Companies developing AI-enabled healthcare solutions should evaluate these issues throughout the product lifecycle, not just when preparing for commercialization.

Common Challenges Companies Face

As AI-enabled clinical decision support software becomes more sophisticated, organizations are facing a more complex regulatory and operational landscape. Product teams often begin with a clear vision for innovation but discover that evolving functionality raises new regulatory questions as products mature. Features added to improve clinical value and utility, like predictive analytics, patient-specific recommendations, or adaptive AI capabilities, can also affect how the FDA views the software.

Organizations also face the challenge of aligning multiple business priorities. Regulatory strategy must keep pace with product development, clinical validation, quality system requirements, investor expectations, commercialization timelines, and customer demands for transparency. These issues frequently require coordination among engineering, clinical, regulatory, legal, quality, and commercial teams, which each bring different perspectives, expertise, and priorities.

Another common challenge is timing. Companies sometimes defer regulatory planning until products are nearing commercialization, only to discover that intended use, software functionality, or marketing claims create regulatory implications that require additional evidence, product modifications, or changes to development plans. Addressing these questions late in development can delay market entry and increase costs. 

As AI capabilities continue to evolve, organizations that proactively evaluate regulatory implications throughout the product lifecycle are generally better positioned to maintain flexibility, support innovation, and respond to changing regulatory expectations.

In Part Two, we explore practical strategies companies can use to address these challenges, including governance, clinical evidence planning, real-world data, and lifecycle management.

How Gardner Law Can Help

Gardner Law advises medical device, digital health, healthcare technology, and life sciences companies on regulatory strategies involving clinical decision support software, AI-enabled Software as a Medical Device (SaMD), AI/ML technologies, and digital health innovation. We help clients evaluate FDA jurisdiction, assess whether software functions may qualify for statutory exclusions or FDA enforcement discretion policies, develop clinical evidence strategies, address real-world data considerations, and align regulatory strategy with commercialization objectives throughout the product lifecycle.